Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sangamo (SGMO) Partner Pfizer (PFE) is Encouraged by Emerging Data from SB-525 - Truist Securities
August 20, 2020 10:57 AM EDTTruist Securities analyst Nicole Germino reiterated a Buy rating and $22.00 price target on Sangamo BioSciences (NASDAQ: SGMO) after talking with management following BMRN's unexpected CRL. Management noted partner Pfizer (NYSE: PFE) is encouraged by emerging data from SB-525
The analyst... More
Baird Reiterates Outperform Rating on The TJX Companies (TJX) Following 2Q
August 20, 2020 7:08 AM EDTBaird analyst Mark R. Altschwager reiterated an Outperform rating and $65.00 price target on The TJX Companies (NYSE: TJX) following the company's 2Q earnings report. Sales in the quarter fell 32% with stores closed ~1/3 of the quarter and open-store-comp sales -3%. Management cited some logistical challenges disrupting... More
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
August 19, 2020 11:30 AM EDTBaird analyst Michael Ulz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $140.00) while maintaining an Outperform rating after the company announced a CRL on Valrox.
The analyst commented, "Overall, we view the update as disappointing and assume at least a two-year delay in time-line."
... More